CFU-F presence is reduced in BM aspirates after alloSCT and correlates with clinical outcome after alloSCT. (A) Overview of all analyzed samples (N = 1273) regarding their origin from individuals with prior alloSCT as well as the underlying diseases in samples obtained after alloSCT. The values of underlying diseases sum up to >100% because of patients with >1 malignant hematological disease. (B) Presence of CFU-F in BM aspirates in individuals depending on previous alloSCT. Only individuals (N = 686) with available data on alloSCT as well as only data for the last BM aspirate for each individual to avoid bias of multiple aspirates in single individuals were included. (C) Multivariate analysis for the presence of CFU-F in BM aspirates of the entire cohort as analyzed in (B). (D) Presence of CFU-F in BM aspirates of 30 patients (paired samples) at different time points before alloSCT, early (d 0 until d +99) and late (after d +180) after alloSCT. (E) Kaplan-Meier analyses for overall survival after alloSCT depending on the presence of CFU-F in BM aspirates. Included were all patients according to the chronologically first sample obtained after alloSCT (N = 196). (F) Presence of CFU-F in BM aspirates obtained after alloSCT in patients with good and poor engraftment. If multiple BM aspirates were available in single patients, the chronologically first sample was included. The discrepancy to (E) in the total number of analyzed patients results from missing data regarding engraftment in one patient.